Video

Research Shows Benefits of Eliquis Over Warfarin For Atrial Fibrillation Patients

Author(s):

While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.

While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.

Jack Lawrence, MD, Vice President, Cardiovascular Specialty Development and Development Lead for Apixaban at Bristol-Myers Squibb, and Christoph Koenen, Vice President, Cardiovascular, at Bristol-Myers discussed the development of the treatment option during the annual American Heart Association Scientific Sessions in Orlando.

With new treatment medications available, particularly when it comes to anticoagulants there is good news for patient care. That good news is expected to continue into the future.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.